Osenvelt (Denosumab)

Denosumab is indicated for several bone‑related conditions where excessive resorption is a concern.

• Postmenopausal osteoporosis: reduces the risk of vertebral, hip and non‑vertebral fractures.
• Osteoporosis in men at high risk of fracture: lowers fracture incidence.
• Bone loss associated with glucocorticoid therapy: mitigates glucocorticoid‑induced bone density loss.
• Prevention of skeletal‑related events in patients with bone metastases from solid tumours: delays onset of pathological fractures and need for radiation or surgery.
• Giant cell tumor of bone: decreases tumor progression and the need for surgical intervention.

• Denosumab is a fully human monoclonal antibody that binds with high affinity to the receptor activator of nuclear factor‑κB ligand (RANKL). By preventing RANKL from interacting with its receptor RANK on osteoclast precursors, it blocks osteoclast formation, reduces their activity and promotes apoptosis, leading to decreased bone resorption and increased bone mineral density.

Adverse reactions to denosumab vary in frequency and severity.

Common Side Effects

• Injection site reactions: pain, redness or swelling at the injection site.
• Musculoskeletal pain: joint or muscle discomfort.
• Upper respiratory infections: nasopharyngitis or sinusitis.
• Dermatologic reactions: rash or eczema.
• Hypocalcaemia: low blood calcium levels, especially in patients with renal impairment.

Serious or Rare Side Effects

• Osteonecrosis of the jaw (ONJ): exposed bone in the maxillofacial region.
• Atypical femoral fractures: low‑energy fractures of the femur shaft.
• Severe hypersensitivity reactions: anaphylaxis or angioedema.
• Severe hypocalcaemia: symptomatic low calcium requiring urgent treatment.
• Infections requiring hospitalization: opportunistic or severe bacterial infections.

When prescribing denosumab, clinicians should consider several safety aspects.

• Calcium and vitamin D supplementation: ensure adequate intake to reduce hypocalcaemia risk.
• Renal function assessment: evaluate before initiation, especially in severe impairment.
• Dental examination: perform prior to therapy to mitigate osteonecrosis of the jaw.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Concomitant anti‑resorptive therapy: avoid overlapping treatment with bisphosphonates.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab may interact with other agents that affect calcium balance or bone metabolism.

Major Interactions (Avoid)

• Calcium‑based antacids taken within 4 hours of injection: may reduce absorption.
• High‑dose vitamin D supplementation without monitoring: can exacerbate hypercalcemia.

Moderate Interactions (Monitor Closely)

• Concomitant bisphosphonates: increased risk of hypocalcaemia and atypical fractures.
• Immunosuppressants (e.g., corticosteroids): heightened infection risk.
• Hormone replacement therapy: may alter bone turnover markers.
• Anticoagulants (warfarin): monitor INR as bone turnover changes can affect vitamin K metabolism.